Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

The Nrf2 transcription factor governs the expression of hundreds genes involved in cell
defense against oxidative stress, the hallmark of numerous diseases such as …

Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle
challenging protein targets deemed undruggable with traditional small molecule inhibitors …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …

Targeted protein degradation is a rapidly exploding drug discovery strategy that uses small
molecules to recruit disease-causing proteins for rapid destruction mainly via the ubiquitin …

Within druggable target space, new small-molecule modalities, particularly covalent
inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists …

Abstract O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-
translational modification that is presented on thousands of nucleocytoplasmic proteins …

Targeted protein degradation (TPD) is a promising approach in drug discovery for degrading
proteins implicated in diseases. A key step in this process is the formation of a ternary …

Current efforts in the proteolysis targeting chimera (PROTAC) field mostly focus on choosing
an appropriate E3 ligase for the target protein, improving the binding affinities towards the …